For Infants with Skull Flattening, Earlier Helmet Therapy Gives Better Results
For infants with skull flattening related to sleep position, starting helmet therapy at a younger age, especially before 24 weeks, increases the treatment success rate, suggests a study in the August issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).
"The present study shows that age at the start of treatment and positional plagiocephaly severity affect the duration and effectiveness of helmet therapy," according to the report by Felix Kunz, DMD, of University Hospital Würzburg, Germany, and colleagues. "These two factors are important predictors on the results of helmet therapy for position-related skull flattening."
Study Measures Effects of Age and Plagiocephaly Severity
Dr. Kunz and colleagues analyzed the results of helmet (molding orthosis) therapy in 144 infants. The infants were divided into groups based on age at starting helmet therapy (before 24 weeks, between 24 and 32 weeks and 32 weeks or later) and severity of plagiocephaly (mild-to-moderate or moderate-to-severe). Treatment success was defined as perceived minimal remaining skull asymmetry.
Infants with positional plagiocephaly have flattening of one side of the head. It may occur in infants who are often laid in the same sleeping position, causing one-sided external molding force on the back of the skull. Positional skull deformities have become more common since the very reasonable recommendation to place babies on their backs to sleep. The "Back to Sleep" campaign (now called "Safe to Sleep") has been highly effective in lowering nationwide rates of sudden infant death syndrome (SIDS).
Helmet therapy reduced skull flattening in all three age groups but was more effective when treatment was started at younger ages. Among infants with mild-to-moderate plagiocephaly, helmet therapy was rated successful in 83 percent of those who started before 24 weeks. The success rate decreased to 69 percent for infants starting treatment between 24 and 32 weeks and 40 percent when treatment was started at 32 weeks or later.
Younger age at treatment also led to a higher success rate for infants with moderate-to-severe plagiocephaly: 50 percent, 30 percent and seven percent, respectively. The duration of helmet therapy was about 19 weeks for infants with early treatment versus 25 weeks for those with later treatment.
Helmet therapy to reshape the growing skull is one of the recommended treatment options for infants with positional plagiocephaly and should be performed after active positioning and physical therapy. Although it is generally recommended that helmet therapy should start early, there is debate over the ideal time to start treatment.
However, few previous studies have addressed the effects of age at start of treatment. The new study did not only use the 3D imaging technique stereophotogrammetry in infants for the first time, it also used real 3D volumetric parameters for analyzing skull asymmetries to investigate the effect of age at start of helmet therapy. Stereophotogrammetry is a precise method for diagnosis and evaluation of skull shape.
Supporting recent guidelines, the findings suggest that helmet therapy should be started early in infants with mild plagiocephaly who don't respond to other treatments such as active repositioning and physical therapy. In more severe cases, helmet therapy should be started immediately.
Dr. Kunz said, "Age and severity have a very significant effect on the reduction in skull asymmetry with helmet therapy. Our study includes an equation that the treating surgeon or physician can use to provide an individualized estimate of the expected reduction in skull asymmetry with helmet therapy."
Click here to read "Head Orthosis Therapy in Positional Plagiocephaly: Influence of Age and Severity of Asymmetry on Effect and Duration of Therapy"
Article: "Head Orthosis Therapy in Positional Plagiocephaly: Influence of Age and Severity of Asymmetry on Effect and Duration of Therapy" (doi: 10.1097/PRS.0000000000003517)
About Plastic and Reconstructive Surgery
For more than 70 years, Plastic and Reconstructive Surgery® has been the one consistently excellent reference for every specialist who uses plastic surgery techniques or works in conjunction with a plastic surgeon. The official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery® brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues.
The American Society of Plastic Surgeons (ASPS) is the world's largest organization of board-certified plastic surgeons. Representing more than 7,000 Member Surgeons, the Society is recognized as a leading authority and information source on aesthetic and reconstructive plastic surgery. ASPS comprises more than 94 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the Society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada. ASPS advances quality care to plastic surgery patients by encouraging high standards of training, ethics, physician practice and research in plastic surgery.
About Wolters Kluwer
Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer reported 2015 annual revenues of €4.2 billion. The group serves customers in over 180 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit www.wolterskluwer.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.